JNJ — JOHNSON & JOHNSON

NYSE · Health Care · Pharmaceuticals · CIK 200406 ·
Last close
$239.08
Market Cap
$575.52B
52W High
$245.80
52W Low
$219.11
ADV30
8,187,663
Next earnings
2026-07-15
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 24,062,000,000 15,956,000,000 6,395,000,000 5,235,000,000 200,894,000,000 21,688,000,000 119,708,000,000
Dec 2025 24,564,000,000 16,596,000,000 5,591,000,000 5,116,000,000 199,210,000,000 19,709,000,000 117,666,000,000
Sep 2025 23,993,000,000 16,690,000,000 7,096,000,000 5,152,000,000 192,816,000,000 18,231,000,000 113,539,000,000
Jun 2025 23,743,000,000 16,115,000,000 6,710,000,000 5,537,000,000 193,389,000,000 18,577,000,000 114,916,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$22,870,000,000
Investing CF
$-24,331,000,000
Financing CF
$-15,431,000,000
CapEx
$-5,457,000,000
Dividends Paid
$-12,523,000,000
Buybacks
$-7,854,000,000
EPS Diluted TTM
$8.65
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
Inventory
$14,583,000,000
Receivables
$22,539,000,000
ST Investments
$363,000,000
EBIT TTM
$25,979,000,000
Pretax Income TTM
$24,940,000,000
Interest Exp TTM
$1,039,000,000
Analysts
24

Yahoo Snapshot (yfinance, live)

Total Revenue
$96,361,996,288
EBITDA
$34,325,000,192
Free Cash Flow
$12,511,375,360
Enterprise Value
$608,453,459,968
Total Cash
$22,051,000,320
Total Debt
$54,987,001,856
Shares Out
2,407,216,971
Trailing EPS
$8.63
Book Value
$33.73
ROE
26.4%
ROA
8.4%
Div Yield
2.24%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 94,193,000,000 25,596,000,000 26,804,000,000 199,210,000,000 117,666,000,000 24,530,000,000
Dec 2024 88,821,000,000 21,249,000,000 14,066,000,000 180,104,000,000 108,614,000,000 24,266,000,000
Dec 2023 85,159,000,000 22,009,000,000 35,153,000,000 167,558,000,000 98,784,000,000 22,791,000,000
Dec 2022 79,990,000,000 21,013,000,000 17,941,000,000 187,378,000,000 110,574,000,000 21,194,000,000

TTM Snapshot

Revenues TTM
$87,156,000,000
NetIncome TTM
$36,847,000,000
OpCashFlow TTM
$0
Assets (Latest)
$180,104,000,000
Forward EPS
$12.70

Max Pain — expiry 2026-06-26

max pain strike: $232.50 · spot: $241.00 · call oi: 7,572 · put oi: 5,631
Expected Move to 2026-06-26: ±$4.02 (1.67%) — implied range $236.97$245.03 · ATM straddle on $240.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ABBV AbbVie Inc. $414.77B $234.76
LLY ELI LILLY & Co $987.23B $1107.08
NVSEF NOVARTIS AG $298.90B $156.65
MRK Merck & Co., Inc. $295.39B $119.60
NVS NOVARTIS AG $292.66B $153.38

News headlines (Yahoo Finance, 1h cache)

SNPD ETF Targets Next Dividend Aristocrats With 10-year Growth Screen
2026-06-24 20:02 · Yahoo
The Number That Could Test AbbVie Stock
2026-06-24 19:32 · Yahoo
Equal Weighted Dividends Across 54 Stocks Deliver 24.7% Returns and Growing Payouts
2026-06-24 19:00 · Yahoo
J&J CEO sends a clear message on the obesity drug boom
2026-06-24 18:47 · Yahoo
The Retirement Portfolio for Grandparents Who Want to Say Yes
2026-06-24 17:22 · Yahoo
Alphabet makes the Dow look more like the Nasdaq
2026-06-24 15:52 · Yahoo
The Dividend Portfolio That Starts Like A Honda And Ends Like A Ferrari
2026-06-24 15:38 · Yahoo
3 Quality Dividend Aristocrats to Buy in June
2026-06-24 14:54 · Yahoo
The Portfolio That Quietly Pays For Two Cruises Every Year
2026-06-24 13:27 · Yahoo
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching
2026-06-24 11:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.